| Stereochemistry | ACHIRAL |
| Molecular Formula | C27H26N4O5S |
| Molecular Weight | 518.584 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(NC2=C(C=NC3=C(C)C=C(C=C23)S(=O)(=O)C4=CC=CC(=C4)C(=O)N(C)C)C(N)=O)=CC=C1
InChI
InChIKey=JFHROPTYMMSOLG-UHFFFAOYSA-N
InChI=1S/C27H26N4O5S/c1-16-11-21(37(34,35)20-10-5-7-17(12-20)27(33)31(2)3)14-22-24(16)29-15-23(26(28)32)25(22)30-18-8-6-9-19(13-18)36-4/h5-15H,1-4H3,(H2,28,32)(H,29,30)
| Molecular Formula | C27H26N4O5S |
| Molecular Weight | 518.584 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
GSK-256066 is a PDE4B inhibitor which was developed by GlaxoSmithKline and tested in phase II of clinical trials for the treatment of COPD, Asthma and Seasonal allergic rhinitis. According to the GSK pipeline, development of GSK-256066 was terminated. There are studies that describes the possibility of repurposing of the drug as antitrypanosomal agents, because it inhibits PDEB1 of Trypanosoma brucei.
